Treatment
Xelox clinical trials
We’re tracking 36 recruiting studies that include Xelox, each written for real people, not researchers, below.
Recruiting studies
- NCT05536102RecruitingPhase 2
Surgery-plus chemo and immunotherapy for HER2-negative gastric cancer
This Phase 2 trial studies whether adding two medicines (XELOX and tislelizumab) and another chemotherapy drug (PLD) around the time of surgery works better and is safe for people with stage III gastric (stomach) cancer. It is designed for tumors that are HER2-negative and PD-1/L1 positive.
ShanghaiAges 18–75 - NCT05702229RecruitingPhase 2
Study of combined medicines for advanced stomach cancer with Claudin18.2
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05970302RecruitingPhase 2
XELOX, bevacizumab, and immunotherapy for metastatic colon cancer
This Phase 2 trial studies a combination treatment (XELOX plus bevacizumab plus an immunotherapy drug) for people with metastatic colon cancer that has certain lab features (MSS/pMMR and RAS-mutated). It aims to see how well the treatment works as a first treatment when the cancer cannot be removed with surgery.
BeijingAges 18 years+ - NCT06128252Recruiting
Taurine with chemotherapy and immunotherapy for gastric cancer
This trial tests whether adding taurine to standard chemo-immunotherapy before surgery helps treat locally advanced gastric cancer. It may be an option for patients whose tumors are PD-L1 positive and can be fully removed with surgery.
Wuhan, HubeiAges 18–75 - NCT06155383RecruitingPhase 2
Surgery and immunotherapy combo for stomach cancer
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06242418RecruitingPhase 2
ctDNA-Guided Chemo for Stage III Colon Cancer
This trial tests whether checking for cancer DNA in your blood (ctDNA) can help doctors decide if you need extra chemotherapy after surgery for stage III colon cancer. It aims to personalize treatment and avoid unnecessary chemo.
Guiyang, GuizhouAges 18–75 - NCT06346197RecruitingPhase 3
Immunotherapy combo for advanced MSI-H stomach/esophageal cancer
This trial tests a combination of immune checkpoint inhibitors (nivolumab, botensilimab, and balstilimab) plus chemotherapy for people with advanced stomach or esophageal cancer that has a specific genetic instability (MSI-H/dMMR) and expresses PD-L1. It may be an option for those who haven't had prior immunotherapy or chemotherapy for advanced disease.
BrestAges 18 years+ - NCT06383559RecruitingPhase 2
Combination therapy for advanced AFP-positive gastric cancer
This trial tests a new combination of chemotherapy (XELOX) plus two immunotherapy/targeted drugs (Sintilimab and Lenvatinib) in people with advanced stomach cancer that produces a high level of a protein called AFP. It aims to see if this combination is safe and can shrink tumors when given as the first treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06609551RecruitingPhase 3
ctDNA-guided chemo choice for elderly colon cancer patients
This trial tests whether using a ctDNA blood test can help choose the best chemotherapy after colon cancer surgery for people aged 70–80. It aims to make treatment more personalized and reduce side effects.
Hangzhou, ZhejiangAges 70–80 - NCT06848465RecruitingPhase 1
Radiation plus chemo-immunotherapy for colon cancer with liver spread
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors and improve outcomes.
Chongqing, Chongqing MunicipalityAges 18–80 - NCT07108127RecruitingPhase 2
Targeted drugs plus chemo for HER2-positive rectal cancer
This trial tests whether a combination of two targeted drugs (trastuzumab and pertuzumab biosimilars) plus chemotherapy can shrink advanced HER2-positive rectal cancer before surgery. It aims to improve response and potentially reduce the need for more aggressive treatments.
BeijingAges 18 years+ - NCT02355379RecruitingPhase 3
Chemo after colon cancer surgery for adults 70 and older
This Phase 3 trial studies whether giving chemotherapy after surgery helps people age 70+ with stage III colon cancer. You would be compared to another planned treatment approach, aiming to lower the chance of the cancer coming back.
Fort de France, GuadeloupeAges 75 years+
Common questions
- Are there clinical trials studying Xelox?
- Yes. Clin2 currently lists 36 recruiting studies that include Xelox, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Xelox trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Xelox an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Xelox or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.